Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2

Carcinogenesis

Volumn 33, Issue 7, 2012, Pages 1406-1411

  Liu, Kangdong ^a,b,c   Park, Chanmi ^a   Li, Shengqing ^b   Lee, Ki Won ^a,d   Liu, Haidan ^a   He, Long ^a   Soung, Nak Kyun ^a   Ahn, Jong Seog ^a   Bode, Ann M ^b   Dong, Ziming ^c   Kim, Bo Yeon ^a   Dong, Zigang ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ZHENGZHOU UNIVERSITY   (China)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALOE EMODIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN KINASE C ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL ANCHORAGE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTHRAQUINONES; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84865161024     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs156     Document Type: Article

References (34)

1. Deocampo,N.D. et al. (2003) The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol., 28, 145-153.
2. Gao,N. et al. (2003) Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun., 310, 1124-1132.
3. Agell,L. et al. (2011) PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod. Pathol, 24, 443-452.
4. Sun,X. et al. (2009) Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res., 29, 1739-1743.
5. Murillo,H. et al. (2001) Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology, 142, 4795-4805.
6. Sircar,K. et al. (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol., 218, 505-513.
7. McCall,P. et al. (2008) Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br. J. Cancer, 99, 1296-1301.
8. Wang,S. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221.
9. de Souza,P.L. et al. (2009) Role of the Akt pathway in prostate cancer. Curr. Cancer Drug Targets, 9, 163-175.
10. Zinzalla,V. et al. (2011) Activation of mTORC2 by association with the ribosome. Cell, 144, 757-768.
11. Sarbassov,D.D. et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
12. Guertin,D.A. et al. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11, 859-871.
13. O'Donnell,A. et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol., 26, 1588-1595.
14. O'Reilly,K.E. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 66, 1500-1508.
15. Sun,S.Y. et al. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res., 65, 7052-7058.
16. Tabernero,J. et al. (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol., 26, 1603-1610.
17. Hay,N. (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 8, 179-183.
18. Shaw,R.J. et al. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424-430.
19. Rosen,N. et al. (2006) AKT and cancer-is it all mTOR? Cancer Cell, 10, 254-256.
20. Yang,Q. et al. (2007) Expanding mTOR signaling. Cell Res., 17, 666-681.
21. Harrington,L.S. et al. (2005) Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci., 30, 35-42.
22. Wan,X. et al. (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene, 26, 1932-1940.
23. Hietakangas,V. et al. (2007) Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth. Genes Dev., 21, 632-637.
24. Guo,J. et al. (2007) Growth inhibitory effects of gastric cancer cells with an increase in S phase and alkaline phosphatase activity repression by aloeemodin. Cancer Biol. Ther., 6, 85-88.
25. Acevedo-Duncan,M. et al. (2004) Aloe-emodin modulates PKC isozymes, inhibits proliferation, and induces apoptosis in U-373MG glioma cells. Int. Immunopharmacol., 4, 1775-1784.
26. Lee,D.E. et al. (2010) 7,3',4'-Trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P+ mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3-kinase. J. Biol. Chem., 285, 21458-21466.
27. Colburn,N.H. et al. (1981) Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc. Natl Acad. Sci. USA, 78, 6912-6916.
28. Guo,J. et al. (2008) Suppression of C-myc expression associates with antiproliferation of aloe-emodin on gastric cancer cells. Cancer Invest., 26, 369-374.
29. Kuo,P.L. et al. (2002) The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. Life Sci., 71, 1879-1892.
30. Guertin,D.A. et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell, 15, 148-159.
31. Roulin,D. et al. (2010) Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol. Cancer, 9, 57.
32. Zhang,F. et al. (2010) mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res., 70, 9360-9370.
33. Xie,X. et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc. Natl Acad. Sci. USA, 108, 6474-6479.
34. Pecere,T. et al. (2000) Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res., 60, 2800-2804.